The FDA is creating a transparency paradox. It is increasingly publishing complete response letters (CRLs), giving insight into why drugs are rejected. Simultaneously, it has drastically cut the number of public advisory committee (AdCom) meetings held before approval decisions, reducing public input and pre-decision transparency.

Lying is an inherent function of all powerful institutions throughout history, not an exception. Meetings in government often focus on 'what' to tell the public, not 'how' to tell the truth. Examples like asbestos in baby powder and the dangers of opioids show a pattern of denial that can last for decades before the truth is admitted.

Even when transparency is mandated, there are levers to control the narrative. The allegation regarding the Epstein files is that they will be redacted to protect powerful figures, with "national security" used as a convenient and difficult-to-challenge justification for censorship.

Facing a negative FDA decision, Replimune has filed a Freedom of Information Act (FOIA) request to investigate why senior FDA leadership allegedly overruled its own review team. This legalistic tactic moves beyond scientific debate into a public challenge of the agency's internal processes and transparency.

A former CIA operative suggests that government secrecy is frequently a tool to hide administrative incompetence, premature announcements, or procedural errors, rather than to cover up nefarious, large-scale conspiracies. This perspective reframes public distrust from calculated malice to bureaucratic failure.

In an unprecedented move, NIH Director Jay Bhattacharya stated in a memo that the Department of Health and Human Services (HHS) forced the departure of NINDS Director Dr. Walter Koreshets, despite Bhattacharya's own strong support for him. This act signals a direct political override of scientific leadership at the agency, creating deep concern about its independence.

The HHS Secretary's unprecedented interview of a candidate for FDA's CEDAR Director marks a significant politicization of a traditionally scientific, civil service position. This shift suggests future directors may need political alignment with the administration, leading to greater risk aversion, erratic decision-making, and less predictability for the biopharma industry.

In an era of narrative warfare, consume government communication by treating it as an official record for future accountability, rather than accepting it as immediate truth. This allows for verification over time.

While most local government data is legally public, its accessibility is hampered by poor quality. Data is often trapped in outdated systems and is full of cumulative human errors, making it useless without extensive cleaning.